Details for Patent: 7,867,996
✉ Email this page to a colleague
Title: | .gamma.-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Abstract: | A .gamma.-Crystalline form of ivabradine hydrochloride of formula (I): ##STR00001## characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics. |
Inventor(s): | Horvath; Stephane (La Chapelle-Saint-Mesmin, FR), Auguste; Marie-Noelle (Orleans, FR), Damien; Gerard (Meung-sur-Loire, FR) |
Assignee: | Les Laboratories Servier (Suresnes Cedex, FR) |
Filing Date: | Aug 27, 2009 |
Application Number: | 12/583,885 |
Claims: | 1. A .gamma.-Crystalline form of ivabradine hydrochloride of formula (I): ##STR00003## having a powder X-ray diffraction diagram exhibiting peaks at 4.2 and 13.4 deg 2 theta. 2. A .gamma.-Crystalline form of ivabradine hydrochloride of formula (I): ##STR00004## having a powder X-ray diffraction diagram exhibiting peaks at 4.2, 13.4, 21.1, 24.2, 24.5 and 26.4 deg 2 theta. 3. A solid pharmaceutical composition comprising as active ingredient the .gamma.-crystalline form of ivabradine hydrochloride of claim 1, in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers. 4. A method for treating a condition selected from angina pectoris, myocardial infarct, and heart failure, such method comprising administering to a human, a therapeutically effective amount of the .gamma.-crystalline form of ivabradine hydrochloride of claim 1. 5. A solid pharmaceutical composition comprising as active ingredient the .gamma.-crystalline form of ivabradine hydrochloride of claim 2, in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers. 6. A method for treating a condition selected from angina pectoris, myocardial infarct, and heart failure, such method comprising administering to a human, a therapeutically effective amount of the .gamma.-crystalline form of ivabradine hydrochloride of claim 2. |